[Skip to content]

European Parkinson's Disease Association
Search our Site

Research papers


Mechanisms research papers

  • Brain The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's DiseaseIn this review, authors outline common pathways shared by both sporadic and familial PD that remarkably and consistently converge at the level of mitochondrial integrity. Furthermore, such knowledge has incontrovertibly established mitochondria as a valid therapeutic target in neurodegeneration. 01 July 2014
  • DNA Oxidized DJ-1 as a possible biomarker of Parkinson's diseaseThis review focuses on the role of DJ-1 in antioxidative defense and the importance of oxidizable Cys-106 in its function. The significance of the identification of early-phase Parkinson's disease biomarkers and the nature of oxidized DJ-1 as a biomarker for Parkinson's disease are discussed here. 01 July 2014
  • Neuron Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's diseaseConsistent with the Braak's proposed pattern of spread, authors contend that axon terminals in the lamina propria of the gut are among the initial targets, with subsequent spread of pathology to the CNS. 01 July 2014
  • DNA Genetic assessment of familial and early-onset Parkinson's disease in a Greek populationResults: In total, five patients (4.5% of the whole population) were identified with the A53T SNCA mutation, two with a heterozygote dosage mutation and one with a heterozygote point mutation in the Parkin gene, and seven patients (10.3% of the familial cohort) with GBA gene mutations. 01 July 2014
  • Brain Up-Regulation of Neurotrophic Factors by Cinnamon & its Metabolite Sodium Benzoate: Therapeutic Implications for ....These results highlight a novel neutrophic property of cinnamon and its metabolite NaB via PKA CREB pathway, which may be of benefit for various neurodegenerative disorders. 30 June 2014
  • Neuron Abrogation of α-synucleinmediated dopaminergic neurodegeneration in LRRK2-deficient ratsStudy data suggest that knocking down LRRK2 may protect from overt cell loss by inhibiting the recruitment of chronically activated proinflammatory myeloid cells. These results may provide value in the translation of LRRK2-targeting therapeutics to conditions where neuroinflammation may underlie aspects of neuronal dysfunction and degeneration. 24 June 2014
  • Brain skeleton activity The expanding universe of disorders of the basal gangliaMoreover, disorders that were thought to be caused by dysfunction of the basal ganglia only, such as Parkinson's disease and Huntington's disease, have diverse abnormalities distributed not only in the brain but also in the peripheral and autonomic nervous systems; this knowledge poses new questions and challenges. Authors discuss advances and the unanswered questions, and ways in which progress might be made. 19 June 2014
  • DNA The genetics of Parkinson's disease: review of current and emerging candidatesMultiple genetic factors combine in different ways to increase or decrease risk, and several of these risk factors need to be identified in order to begin unraveling the causative pathways leading to the different forms of PD. In this review, we present current and emerging PD candidate genes to help explain the pathways leading to neurodegeneration. 17 June 2014
  • Journal of Clinical Investigation Vol 125 Iss 3 shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease modelThese data show that α-synuclein knockdown is neuroprotective in the rotenone model of PD and indicate that endogenous α-synuclein contributes to the specific vulnerability of dopaminergic neurons to systemic mitochondrial inhibition. Our findings are consistent with a model in which genetic variants influencing α-synuclein expression modulate cellular susceptibility to environmental exposures in PD patients. shRNA targeting the SNCA transcript should be further evaluated as a possible neuroprotective thera 15 June 2014
  • Neuron Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort StudyThis study suggests centrally-acting dihydropyridine CCB use and high cumulative doses of ACEIs and ARBs may associate with a decreased incidence of PD in hypertensive patients. Further long-term follow-up studies are needed to confirm the potential beneficial effects of antihypertensive agents in PD. 09 June 2014
Page: [10-] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [+21]